Gla - galactosidase, alpha Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 363494

Summary

Enables alpha-galactosidase activity and galactoside binding activity. Predicted to be involved in several processes, including glycosylceramide catabolic process; negative regulation of nitric oxide biosynthetic process; and negative regulation of nitric-oxide synthase activity. Located in lysosome. Used to study Fabry disease and lysosomal storage disease. Human ortholog(s) of this gene implicated in Fabry disease. Orthologous to human GLA (galactosidase alpha). [provided by Alliance of Genome Resources, Apr 2022]

Gla Products (1)

mRNA Protein Name
NM_001108820.3 NP_001102290.2 alpha-galactosidase A

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables alpha-galactosidase activity IDA
IDA: Inferred from direct assay
8702598 RGD
enables alpha-galactosidase activity IMP
IMP: Inferred from mutant phenotype
8717430 RGD
enables galactoside binding IDA
IDA: Inferred from direct assay
8702598 RGD
Biological Process GO Annotation Evidence References Source
involved in glycosphingolipid catabolic process IMP
IMP: Inferred from mutant phenotype
34320241 RGD
involved in lipid storage IMP
IMP: Inferred from mutant phenotype
34541380 RGD
involved in platelet activation IMP
IMP: Inferred from mutant phenotype
34320241 RGD
involved in platelet aggregation IMP
IMP: Inferred from mutant phenotype
34320241 RGD
involved in regulation of axon diameter IMP
IMP: Inferred from mutant phenotype
34541380 RGD
involved in regulation of locomotion involved in locomotory behavior IMP
IMP: Inferred from mutant phenotype
36660199 RGD
involved in sleep IMP
IMP: Inferred from mutant phenotype
36660199 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

alpha-galactosidase A

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B2172 Vitamin K 98.70% Unkown

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-112499 Menaquinone-7 Activator 98.51% Phase 2
HY-112499R Menaquinone-7 (Standard) 98.27% Phase 2

Pre-clinical Phase

Bioactive Molecules (22)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-118135 4-Methylumbelliferyl-α-D-galactopyranoside 99.96% Unkown
HY-W009276 γ-Linolenic Acid methyl ester Inducer 98.08% Unkown
HY-112499S1 Menaquinone-7-13C6 96.0% Unkown
HY-144003 BAY-R 1005 / Unkown
HY-165180 Lyso-sulfatide (bovine) sodium Inhibitor / Unkown
HY-172552 RECTAS-2.0 / Unkown
HY-E71229 α-Galactosidase 110A, Bacteroides fragilis / Unkown
HY-E71229A α-Galactosidase 110A, Bacteroides thetaiotaomicron / Unkown
HY-E71230 α-Galactosidase 27A, Clostridium cellulolyticum / Unkown
HY-E71231 α-Galactosidase 4A, Bacillus halodurans / Unkown
HY-E71232 α-Galactosidase 95A, Bacteroides ovatus / Unkown
HY-E71233 α-Galactosidase 97A, Bacteroides thetaiotaomicron / Unkown
HY-E71234 α-Galactosidase 97B, Bacteroides thetaiotaomicron / Unkown
HY-RS05463 GLA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS09043 NAT8 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-112499S Menaquinone-7-d7 / Unkown
HY-131642 L-γ-Carboxyglutamic acid Antagonist / Unkown
HY-185226 γ-Linolenic acid NHS ester / Unkown
HY-D3589 BC-GLA 99.64% Unkown
HY-RS17243 Gla Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23697 Gla Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W1122690 Vitamin K-d7 / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gla NCBI NCBI:2717